Call Options

2 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$52.05 - $65.0 $3.74 Million - $4.67 Million
71,800 Added 89.19%
152,300 $9.18 Million
Q3 2022

Nov 14, 2022

BUY
$25.16 - $60.63 $2.03 Million - $4.88 Million
80,500 New
80,500 $4.88 Million

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $646M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Pfm Health Sciences, LP Portfolio

Follow Pfm Health Sciences, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pfm Health Sciences, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pfm Health Sciences, LP with notifications on news.